$CRL · CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SEC Filings
Position Tracker tracks 3 SEC EDGAR filings for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. ($CRL) from November 4, 2026 through November 9, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 2 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$CRL 8-K — CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
A ~$470M strategic acquisition deepens Charles River's high-growth clinical bioanalysis position and is expected to be EPS-accretive after 2027.
$CRL 10-Q — CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
The headline profit surge is tax-accounting driven, masking a core revenue decline that investors should weigh carefully.
$CRL 8-K — CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
A second straight quarter of organic growth plus a guidance raise confirms the biopharma demand recovery thesis for the CRO leader.